Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair

[1]  J. Meyerhardt,et al.  The relationship between primary tumor sidedness and prognosis in colorectal cancer. , 2016 .

[2]  Preet Paul Singh,et al.  Immune checkpoints and immunotherapy for colorectal cancer , 2015, Gastroenterology report.

[3]  Jeffrey S. Morris,et al.  The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.

[4]  E. Lau.  Mismatch repair deficiency predicts benefit of anti-PD-1 therapy. , 2015, The Lancet. Oncology.

[5]  T. Aparicio,et al.  PD-1 blockade in tumors with mismatch-repair deficiency , 2015 .

[6]  D. Chang,et al.  Lynch‐like syndrome: Characterization and comparison with EPCAM deletion carriers , 2015, International journal of cancer.

[7]  R. Riechelmann,et al.  The effects of palliative chemotherapy in metastatic colorectal cancer patients with an ECOG performance status of 3 and 4. , 2015, Clinical colorectal cancer.

[8]  H. Lynch,et al.  570PTHYMIDYLATE SYNTHASE OVER-EXPRESSION UNDERLIES THE OBSERVED LACK OF 5-FU THERAPY BENEFIT FOR MSI-H COLORECTAL CANCERS. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  E. Mello,et al.  Prognostic implication of mucinous histology in resected colorectal cancer liver metastases. , 2014, Surgery.

[10]  S. Friend,et al.  Colorectal Cancer Subtyping Consortium (CRCSC) identification of a consensus of molecular subtypes. , 2014 .

[11]  P. Gibbs,et al.  Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Hyuk Hur,et al.  Prognostic Value of Mucinous Histology Depends on Microsatellite Instability Status in Patients with Stage III Colon Cancer Treated with Adjuvant FOLFOX Chemotherapy: A Retrospective Cohort Study , 2013, Annals of Surgical Oncology.

[13]  Á. Carracedo,et al.  Risk of cancer in cases of suspected lynch syndrome without germline mutation. , 2013, Gastroenterology.

[14]  P. Demetter,et al.  Mucinous subtype as prognostic factor in colorectal cancer: a systematic review and meta-analysis , 2012, Journal of Clinical Pathology.

[15]  P. Gibbs,et al.  Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer , 2011, Cancer.

[16]  Yoon-Koo Kang,et al.  Association between deficient mismatch repair system and efficacy to irinotecan‐containing chemotherapy in metastatic colon cancer , 2011, Cancer science.

[17]  N. Lindor,et al.  Lynch syndrome and MYH-associated polyposis: review and testing strategy. , 2011, Journal of clinical gastroenterology.

[18]  Joon-Oh Park,et al.  The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer , 2010, Medical oncology.

[19]  K. Öhrling,et al.  Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer , 2010, Acta oncologica.

[20]  R. Labianca,et al.  Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Sargent,et al.  Clinical implications of microsatellite instability in sporadic colon cancers , 2009, Current opinion in oncology.

[22]  B. Uzzan,et al.  Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysis. , 2009, Anticancer research.

[23]  C. Compton,et al.  Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Ligtenberg,et al.  Deficient mismatch repair system in patients with sporadic advanced colorectal cancer , 2009, British Journal of Cancer.

[25]  Peter W. Laird,et al.  Molecular Characterization of MSI-H Colorectal Cancer by MLHI Promoter Methylation, Immunohistochemistry, and Mismatch Repair Germline Mutation Screening , 2008, Cancer Epidemiology Biomarkers & Prevention.

[26]  K. Schulmann,et al.  Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group , 2008, International Journal of Colorectal Disease.

[27]  W. Scheithauer,et al.  Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Cucherousset,et al.  Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer. , 2007, Anticancer research.

[29]  J. Warusavitarne,et al.  The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer , 2007, International Journal of Colorectal Disease.

[30]  J. Jass.  Classification of colorectal cancer based on correlation of clinical, morphological and molecular features , 2007, Histopathology.

[31]  M. Ducreux,et al.  Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. , 2003, Cancer research.

[32]  Daniel J Sargent,et al.  Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. , 2003, The New England journal of medicine.

[33]  King-Jen Chang,et al.  High‐frequency microsatellite instability predicts better chemosensitivity to high‐dose 5‐fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection , 2002, International journal of cancer.

[34]  Robert Brown,et al.  Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. , 2001, The American journal of pathology.

[35]  G. Strathdee,et al.  A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer , 1999, Oncogene.

[36]  T. Kunkel,et al.  The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. , 1998, Cancer research.

[37]  A. V. D. Van Der Zee,et al.  hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents , 1997, Oncogene.

[38]  C. Macleod,et al.  In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. , 1997, Cancer research.

[39]  S. Aebi,et al.  The role of DNA mismatch repair in platinum drug resistance. , 1996, Cancer research.

[40]  P. Hoff,et al.  Modified FLOX as first-line chemotherapy for metastatic colorectal cancer patients in the public health system in Brazil: Effectiveness and cost-utility analysis. , 2013, Molecular and clinical oncology.

[41]  E. Chiorean.  DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy , 2011 .

[42]  P. Loehrer.  High Thymidylate Synthase Expression in Colorectal Cancer With Microsatellite Instability: Implications for Chemotherapeutic Strategies , 2006 .